Pathomorphological characteristics of bisphosphonate osteonecrosis of the jaws


Cite item

Full Text

Abstract

The article is devoted to the bisphosphonate osteonecrosis of the jaw, which is a complication of bisphosphonate therapy in cancer patients. The article presents the results of a study of osteonecrosis of the jaw in 40 patients with a history of antiresorptive therapy. This group of patients is formed by a retrospective analysis of inpatient and outpatients department patients chemotherapy Stavropol clinical advisory diagnostic Oncology Center and the Department of Maxillofacial Surgery Municipal Clinical Emergency Hospital of Stavropol for the years 2011-2015. The distribution of patients was by sex, age, urbanization, type of primary cancer pathology. In 30 patients (75%) decided to hold the surgical treatment - curettage (n = 10), sequestrectomy (n = 11), partial resection of the jaw (n = 9), with the result that received the opportunity to specify a unique pathologic pattern bisphosphonate osteonecrosis of the jaw in a three histological types: total osteonecrosis (43,33 ± 9,05%), aseptic osteonecrobiosis (33,33 ± 8,61%), osteonecrosis with regeneration phenomena (23,33 ± 7,72%). Informative value of this method in terms of predicting disease outcome. Using Fisher’s exact test (two-way) found that the likelihood of clinical cure was significantly higher (p <0.05) among patients whose tissue samples obtained were identified osteonecrosis regeneration phenomena, than among patients with osteonecrobiosis. In the group with total osteonecrosis failed after a single surgical intervention to eliminate the portion of bone denudation. It was found that the clinical course of bisphosphonate osteonecrosis histologically comparable with degenerative and regenerative manifestations of varying degrees of severity, and the detailed study of the surgical specimens allows to predict the success of treatment of this disease.

About the authors

Elena Mikhaylovna Spevak

«Stavropol state medical University» Ministry of healthcare of the Russian Federation

Email: cymbal.elena@mail.ru
post-graduate student of the Department of Operative Dentistry and Maxillofacial Surgery «Stavropol State Medical University» 355017, Stavropol

D. Yu Christoforando

«Stavropol state medical University» Ministry of healthcare of the Russian Federation

355017, Stavropol

References

  1. Ruggiero S.L., Dodson T.B., Fantasia J., Goodday R., Aghaloo T., Mehrotra B. et al. American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw-2014 update. J. Oral. Maxillofac. Surg. 2014; 72(10): 1938-56.
  2. Khosla S., Burr D., Cauley J., Cauley J., Dempster D.W., Ebeling P.R., Felsenberget D. et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J. Bone Miner. Res. 2007; 22: 1479-91.
  3. Marx R.E. Pamidronate (Aredia) and Zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J. Oral Maxillofac. Surg. 2003; 61: 1115-7.
  4. Bamias A., Kastritis E., Bamia C., Moulopoulos L.A., Melakopoulos I., Bozas G. et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors. J. Clin. Oncol. 2005; 23: 8580.
  5. Dimopoulos M., Kastritis E., Anagnostopoulos A., Melakopoulos I., Gika D., Moulopoulos L.A. et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: Evidence of increased risk after treatment with zoledronic acid. Haematologica. 2006; 91: 968.
  6. Bantis A., Zissimopoulos A., Sountoulides P., Bantis A., Zissimopoulos A., Sountoulides P. et al. Bisphosphonate-induced osteonecrosis of the jaw in patients with bone metastatic, hormone-sensitive prostate cancer. Risk factors and prevention strategies. Tumori. 2011; 97: 479-83.
  7. Tennis P., Rothman K.J., Bohn R.L., Tan H., Zavras A., Laskarides C. et al. Incidence of osteonecrosis of the jaw among users of bisphosphonates with selected cancers or osteoporosis. Pharmacoepidemiol. Drug Saf. 2012; 21: 810-7.
  8. Жабина А.С. Роль бисфосфонатов для профилактики и лечения метастазов в кости. Практ. онкол. 2011; 12(3): 124-31.
  9. Сулейманов А.М. Бисфосфонатные остеонекрозы челюстей. Медицинский. вестник Башкортостана. 2012; 7(2): 112-5.
  10. Тарасенко С.В., Дробышев А.Ю., Шипкова Т.П., Жукова Н.А. и др. Тактика лечения больных с бисфосфонатным остеонекрозом челюстей. Российская стоматология. 2012; (2): 3-13.
  11. Khan A.A., Morrison A., Hanley D.A., Felsenberg D., McCauley L.K., O’Ryan F. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J. Bone Miner. Res. 2015; 30(1): 3-23. doi: 10.1002/jbmr.2405.
  12. Заславская Н.А., Дробышев А.Ю., Волков А.Г., Лежнев Д.А. Диагностика и лечение остеонекрозов челюстей у больных злокачественными новообразованиями, получающих терапию антирезорбтивными препаратами (бисфосфонаты, деносумаб). Медицинский вестник МВД. 2014; 68(1): 14-6.

Copyright (c) 2016 Eco-Vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies